Subhashis Banerjee, M.D., is a trained rheumatologist and immunologist who brings over two decades of clinical development experience in autoimmune diseases, most recently as Disease Area Head for Rheumatology and Dermatology Global Development at Bristol Myers Squibb (BMS), and Senior Vice President (SVP), Clinical Development at VYNE Therapeutics, Inc. Prior to joining Artiva, Dr. Banerjee served as SVP of Clinical Development at VYNE Therapeutics Inc., where he led the clinical development of BET inhibitors across many immune-mediated conditions. Prior to that, he served as Vice President and Disease Area Head of Rheumatology and Dermatology at BMS, where he played a key role in the development strategy of immunology assets across multiple platforms for several immune-mediated diseases. During his tenure at BMS, Dr. Banerjee served as the global lead for mid- to late-stage clinical development of Sotyktu® (deucravacitinib), Orencia® (abatacept) and clazakizumab (anti-IL-6 antibody) for the treatment of a variety of rheumatology indications including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), lupus nephritis, idiopathic inflammatory myopathy (IIM) and Sjögren’s Disease. Prior to working at BMS, Dr. Banerjee served as a global clinical program lead at Eli Lilly and Company on the clinical development of Taltz® (ixekizumab, anti-IL-17 antibody) in RA, psoriasis, psoriatic arthritis and ankylosing spondylitis that led to marketing authorizations in the latter three indications. Earlier in his career, Dr. Banerjee supported the clinical development of Xeljanz® (tofacitinib) at Pfizer Inc., and early development activities of Humira® (adalimumab) at AbbVie. Dr. Banerjee received his medical degree from Christian Medical College in Vellore, India, and he completed his residency in internal medicine at St. Vincent Hospital in Worcester, Massachusetts. He trained in immunology and autoimmune diseases at the Mayo Clinic and McGill University prior to joining the industry.
What is Subhashis Banerjee's net worth?
The estimated net worth of Subhashis Banerjee is at least $1.42 million as of May 19th, 2026. Banerjee owns 144,963 shares of Artiva Biotherapeutics stock worth more than $1,423,537 as of June 23rd. This net worth approximation does not reflect any other assets that Banerjee may own. Learn More about Subhashis Banerjee's net worth.
How do I contact Subhashis Banerjee?
Has Subhashis Banerjee been buying or selling shares of Artiva Biotherapeutics?
During the last quarter, Subhashis Banerjee has sold $63,403.37 of Artiva Biotherapeutics stock. Most recently, Subhashis Banerjee sold 7,037 shares of the business's stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $9.01, for a transaction totalling $63,403.37. Following the completion of the sale, the insider now directly owns 144,963 shares of the company's stock, valued at $1,306,116.63. Learn More on Subhashis Banerjee's trading history.
Who are Artiva Biotherapeutics' active insiders?
Are insiders buying or selling shares of Artiva Biotherapeutics?
In the last year, Artiva Biotherapeutics insiders bought shares 9 times. They purchased a total of 9,501,755 shares worth more than $103,750,036.39. In the last year, insiders at the sold shares 9 times. They sold a total of 113,602 shares worth more than $741,174.90. The most recent insider tranaction occured on June, 16th when Director Ra Capital Management, L.P. bought 124,893 shares worth more than $1,110,298.77. Insiders at Artiva Biotherapeutics own 21.4% of the company.
Learn More about insider trades at Artiva Biotherapeutics. Information on this page was last updated on 6/16/2026.
